ASP1517 Phase 3 Clinical Trial - A Multi-center, Randomized, 2-arm Parallel, Double-blind, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia.

Trial Profile

ASP1517 Phase 3 Clinical Trial - A Multi-center, Randomized, 2-arm Parallel, Double-blind, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Roxadustat (Primary) ; Darbepoetin alfa
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 11 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Apr 2017 Planned End Date changed from 1 Sep 2017 to 30 Jun 2018.
    • 14 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top